Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG101 for Semaglutide-Induced GI Side Effects
NCT06500429Phase 2Completed
- Sponsor
- Neurogastrx, Inc.
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NG101 in drug-induced nausea, Drug-induced vomiting, sponsored by Neurogastrx, Inc.. Started Jun 2024; status: completed.
02
Drugs
NG101
03
Conditions
drug-induced nauseaDrug-induced vomiting
Beyond the preview
Go deeper on NCT06500429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500429.